DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Bo-Seong | ko |
dc.contributor.author | Cha, Jeong Seok | ko |
dc.contributor.author | Hwang, Insu | ko |
dc.contributor.author | Kim, Uijin | ko |
dc.contributor.author | Adolf-Bryfogle, Jared | ko |
dc.contributor.author | Coventry, Brian | ko |
dc.contributor.author | Cho, Hyun-Soo | ko |
dc.contributor.author | Kim, Kyun-Do | ko |
dc.contributor.author | Oh, Byung-Ha | ko |
dc.date.accessioned | 2022-01-24T06:42:26Z | - |
dc.date.available | 2022-01-24T06:42:26Z | - |
dc.date.created | 2022-01-24 | - |
dc.date.created | 2022-01-24 | - |
dc.date.created | 2022-01-24 | - |
dc.date.created | 2022-01-24 | - |
dc.date.created | 2022-01-24 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.citation | MABS, v.14, no.1 | - |
dc.identifier.issn | 1942-0862 | - |
dc.identifier.uri | http://hdl.handle.net/10203/292018 | - |
dc.description.abstract | Coronavirus disease 2019, caused by SARS-CoV-2, remains an on-going pandemic, partly due to the emergence of variant viruses that can "break-through" the protection of the current vaccines and neutralizing antibodies (nAbs), highlighting the needs for broadly nAbs and next-generation vaccines. We report an antibody that exhibits breadth and potency in binding the receptor-binding domain (RBD) of the virus spike glycoprotein across SARS coronaviruses. Initially, a lead antibody was computationally discovered and crystallographically validated that binds to a highly conserved surface of the RBD of wild-type SARS-CoV-2. Subsequently, through experimental affinity enhancement and computational affinity maturation, it was further developed to bind the RBD of all concerning SARS-CoV-2 variants, SARS-CoV-1 and pangolin coronavirus with pico-molar binding affinities, consistently exhibited strong neutralization activity against wild-type SARS-CoV-2 and the Alpha and Delta variants. These results identify a vulnerable target site on coronaviruses for development of pan-sarbecovirus nAbs and vaccines. | - |
dc.language | English | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.title | Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants | - |
dc.type | Article | - |
dc.identifier.wosid | 000743060500001 | - |
dc.identifier.scopusid | 2-s2.0-85123348001 | - |
dc.type.rims | ART | - |
dc.citation.volume | 14 | - |
dc.citation.issue | 1 | - |
dc.citation.publicationname | MABS | - |
dc.identifier.doi | 10.1080/19420862.2021.2021601 | - |
dc.contributor.localauthor | Oh, Byung-Ha | - |
dc.contributor.nonIdAuthor | Cha, Jeong Seok | - |
dc.contributor.nonIdAuthor | Hwang, Insu | - |
dc.contributor.nonIdAuthor | Kim, Uijin | - |
dc.contributor.nonIdAuthor | Adolf-Bryfogle, Jared | - |
dc.contributor.nonIdAuthor | Coventry, Brian | - |
dc.contributor.nonIdAuthor | Cho, Hyun-Soo | - |
dc.contributor.nonIdAuthor | Kim, Kyun-Do | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Computational antibody discovery | - |
dc.subject.keywordAuthor | Sars-CoV-2 | - |
dc.subject.keywordAuthor | emerging variants | - |
dc.subject.keywordAuthor | broadly neutralizing antibody | - |
dc.subject.keywordAuthor | broad-spectrum vaccine | - |
dc.subject.keywordPlus | SPIKE PROTEIN | - |
dc.subject.keywordPlus | X-RAY | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | COVID-19 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.